Science

Aug 21, 2025, 06:29

Moazzam Shahzad: The Impact of MRD Status after Matched Donor alloHCT in AML

Moazzam Shahzad, Hematologist-Oncologist at H. Lee Moffitt Cancer Center and Research Institute, shared a post on X about a paper he co-authored with colleagues published in Clinical Lymphoma Myeloma and Leukemia:

“Our recent publication in CLML explores the impact of MRD status after matched donor alloHCT in AML.”

Title: Impact of Measurable Residual Disease Status on Outcomes after HLA-Matched Donor Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Authors: Moazzam Shahzad, Muhammad Kashif Amin, Sohaib Irfan, Abhinav Vyas, Rania Ahsan, Sibgha Gull Chaudhary, Iqra Anwar, Matthew McGuirk, Raheel Iftikhar, Haitham Abdelhakim, Anurag K. Singh, Mehdi Hamadani, Joseph P. Mcguirk, Muhammad Umair Mushtaq

You can read the Full Article on Clinical Lymphoma Myeloma and Leukemia.

Moazzam Shahzad: The Impact of MRD Status after Matched Donor alloHCT in AML

More posts featuring Moazzam Shahzad.

Abhinav Vyas Acute Myeloid Leukemia Allogeneic Hematopoietic Cell Transplantation AML Anurag K. Singh cancer Haitham Abdelhakim Iqra Anwar Joseph P. McGuirk Matthew McGuirk Mehdi Hamadani Moazzam Shahzad Muhammad Kashif Amin Muhammad Umair Mushtaq OncoDaily Oncology Raheel Iftikhar Rania Ahsan Sibgha Gull Chaudhary Sohaib Irfan

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding